- RAPT Therapeutics Inc Corporate Update Call TranscriptFeb 20, 2024
- RAPT Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- Rapt Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Rapt Therapeutics Inc at Goldman Sachs Healthcare Conference TranscriptJun 12, 2023
- Rapt Therapeutics Inc Annual Shareholders Meeting TranscriptMay 24, 2023
- Rapt Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) TranscriptFeb 14, 2023
- Rapt Therapeutics Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Rapt Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Rapt Therapeutics Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Rapt Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) - Presentation TranscriptSep 12, 2022
- Rapt Therapeutics Inc at Wells Fargo Healthcare Conference TranscriptSep 08, 2022
- Rapt Therapeutics Inc at Wells Fargo Virtual Healthcare Conference TranscriptSep 09, 2021
- Rapt Therapeutics Inc at UBS Global Healthcare Virtual Conference TranscriptMay 24, 2021
Rapt Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
All right, hello, everyone. My name is Prakhar Agrawal. I'm a biotech analyst at Cantor. Welcome to day one of Cantor's Global Healthcare Conference. For our next session, we are very excited to host RAPT Therapeutics. And representing RAPT is Brian Wong, President and CEO.
Brian will be giving a presentation. Brian, take it away.
Thanks, Prakhar. And thanks, everyone, for your interest. I'm very pleased today to introduce you to RAPT Therapeutics. We are focused on the discovery and development of novel oral drugs that target critical immune drivers underlying both inflammation and cancer. Our proprietary discovery engine has allowed the acceleration of the discovery of multiple clinically derisked assets that address large market opportunities.
Our lead asset in inflammation is called RPT193. This is a once-daily oral agent that targets inflammatory Th2 cells, which is the same cellular target that's reduced by drugs such as Dupixent.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)